See more : Knowledge Economic City Company (4310.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Reneo Pharmaceuticals, Inc. (RPHM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reneo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PYC Therapeutics Limited (PYC.AX) Income Statement Analysis – Financial Results
- MAS Gold Corp. (MSGCF) Income Statement Analysis – Financial Results
- BlackRock Greater Europe Investment Trust plc (BRGE.L) Income Statement Analysis – Financial Results
- Tekumo, Inc. (TKMO) Income Statement Analysis – Financial Results
- Astec LifeSciences Limited (ASTEC.NS) Income Statement Analysis – Financial Results
Reneo Pharmaceuticals, Inc. (RPHM)
About Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 525.00K | 529.00K | 50.00K | 37.00K | 34.00K |
| Gross Profit | -525.00K | -529.00K | -50.00K | -37.00K | -34.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.61M | 37.71M | 28.17M | 15.94M | 13.10M |
| General & Administrative | 25.79M | 16.14M | 11.65M | 3.61M | 2.38M |
| Selling & Marketing | 26.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.79M | 16.14M | 11.65M | 3.61M | 2.38M |
| Other Expenses | 650.00K | 1.89M | 48.00K | 87.00K | 3.04M |
| Operating Expenses | 83.05M | 53.85M | 39.82M | 19.55M | 15.47M |
| Cost & Expenses | 83.05M | 53.85M | 39.82M | 19.55M | 15.47M |
| Interest Income | 0.00 | 1.89K | 48.00 | 87.00K | 456.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 170.00K | 529.00K | 50.00K | 37.00K | 34.00K |
| EBITDA | -82.23M | -53.76M | -39.77M | -19.52M | -15.44M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.05M | -53.85M | -39.82M | -19.55M | -15.47M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.67M | 1.89M | 48.00K | 87.00K | 3.04M |
| Income Before Tax | -77.39M | -51.96M | -39.77M | -19.47M | -12.44M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 650.00K | -1.89M | -186.56K | -169.30K | -137.86K |
| Net Income | -77.39M | -50.06M | -39.77M | -19.47M | -12.44M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -25.23 | -2.04 | -2.19 | -0.80 | -1.60 |
| EPS Diluted | -25.23 | -2.04 | -2.19 | -0.80 | -1.60 |
| Weighted Avg Shares Out | 3.07M | 24.50M | 18.14M | 24.21M | 7.79M |
| Weighted Avg Shares Out (Dil) | 3.07M | 24.50M | 18.14M | 24.21M | 7.79M |
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will be participating...
Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results
First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies
Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction
SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced today that Jefferies LLC, SVB Leerink...
Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results
SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter...
Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will present and...
US IPO Weekly Recap: The IPO Market Cools Off In A 2 IPO Week
Just two IPOs priced this past week, raising $222 million as the US IPO market continued to cool down. The IPO pipeline remained active, with 13 IPOs and 14 SPACs submitting initial filings this week.
Two Biotechs Are Set to Start Trading Today
VectivBio Holding and Reneo Pharmaceuticals are making their market debuts on Nasdaq.
Reneo Pharmaceuticals Announces Pricing of Initial Public Offering
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced the pricing of its initial public offering...
Source: https://incomestatements.info
Category: Stock Reports